Literature DB >> 12715181

Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice.

Giuseppe Marano1, Sergio Palazzesi, Alessandro Vergari, Liviana Catalano, Simona Gaudi, Claudia Testa, Rossella Canese, Giulia Carpinelli, Franca Podo, Alberto U Ferrari.   

Abstract

Controversy exists whether the development of left-ventricular hypertrophy (LVH) is a mechanism able to prevent cardiac dysfunction under conditions of pressure overload. In the present study we re-assessed the long-term effects of attenuating LVH by using L- and D-propranolol, which are equally able to inhibit the development of LVH induced by aortic banding. The aortic arch was banded proximal to the left common carotid artery in 71 CD-1 mice that were then assigned randomly to receive L-propranolol, D-propranolol (both 80 mg/kg per day) or vehicle. Concurrently, sham-operated mice were given L-propranolol, D-propranolol or vehicle. LV dimension and performance were evaluated under isoflurane anaesthesia by cine-magnetic resonance imaging, echocardiography and cardiac catheterization up to 8 weeks after surgery. After 2 weeks of pressure overload, the vehicle-treated banded mice had enhanced LV weight, normal chamber size and increased relative wall thickness (concentric hypertrophy), whereas L-propranolol- or D-propranolol-banded mice showed a markedly blunted hypertrophic response, i.e. normal chamber size and normal relative wall thickness, as well as preserved systolic LV chamber function. After 4 weeks, the vehicle-treated banded mice showed LV enlargement with a reduced relative wall thickness (eccentric remodelling) and a clear-cut deterioration in LV systolic function. In contrast, L-propranolol- or D-propranolol-treated banded mice showed normal chamber size with a normal relative wall thickness and preserved systolic function. A distinct histological feature was that in banded mice, L-or D-propranolol attenuated the development of cardiomyocyte hypertrophy but not the attendant myocardial fibrosis. At the 8-week stage, LV dysfunction was present in propranolol-treated banded mice although it was much less severe than in vehicle-treated banded mice. It is concluded that (i) deterioration of LV systolic performance is delayed if LV hypertrophy is inhibited, (ii) banding-induced deterioration of LV systolic function is associated with LV eccentric remodelling and (iii) the antihypertrophic effect of propranolol is due to a selective action on cardiomyocytes rather than on collagen accumulation

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715181     DOI: 10.1007/s00424-003-1059-2

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  10 in total

1.  Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension : novel molecular adaptation to systolic load in absence of hypertrophy.

Authors:  J Bartunek; E O Weinberg; M Tajima; S Rohrbach; S E Katz; P S Douglas; B H Lorell
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

2.  Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.

Authors:  M Shimoyama; D Hayashi; E Takimoto; Y Zou; T Oka; H Uozumi; S Kudoh; F Shibasaki; Y Yazaki; R Nagai; I Komuro
Journal:  Circulation       Date:  1999-12-14       Impact factor: 29.690

3.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload.

Authors:  J A Hill; M Karimi; W Kutschke; R L Davisson; K Zimmerman; Z Wang; R E Kerber; R M Weiss
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

4.  Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade.

Authors:  Giuseppe Marano; Sergio Palazzesi; Antonello Fadda; Alessandro Vergari; Alberto U Ferrari
Journal:  J Hypertens       Date:  2002-04       Impact factor: 4.844

5.  Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.

Authors:  Y Sakata; T Masuyama; K Yamamoto; N Nishikawa; H Yamamoto; H Kondo; K Ono; K Otsu; T Kuzuya; T Miwa; H Takeda; E Miyamoto; M Hori
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

6.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure.

Authors:  T Meguro; C Hong; K Asai; G Takagi; T A McKinsey; E N Olson; S F Vatner
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

7.  Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats.

Authors:  E Oie; R Bjørnerheim; O P Clausen; H Attramadal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-06       Impact factor: 4.733

8.  LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice.

Authors:  A Nakamura; D G Rokosh; M Paccanaro; R R Yee; P C Simpson; W Grossman; E Foster
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

9.  Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Authors:  Giovanni Esposito; Antonio Rapacciuolo; Sathyamangla V Naga Prasad; Hideyuki Takaoka; Steven A Thomas; Walter J Koch; Howard A Rockman
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

10.  Use of tibial length to quantify cardiac hypertrophy: application in the aging rat.

Authors:  F C Yin; H A Spurgeon; K Rakusan; M L Weisfeldt; E G Lakatta
Journal:  Am J Physiol       Date:  1982-12
  10 in total
  5 in total

1.  Pressure overload induces early morphological changes in the heart.

Authors:  Colby A Souders; Thomas K Borg; Indroneal Banerjee; Troy A Baudino
Journal:  Am J Pathol       Date:  2012-09-04       Impact factor: 4.307

2.  Propranolol causes a paradoxical enhancement of cardiomyocyte foetal gene response to hypertrophic stimuli.

Authors:  M Patrizio; M Musumeci; T Stati; P Fasanaro; S Palazzesi; L Catalano; G Marano
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

3.  Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.

Authors:  Caryn Hampton; Raymond Rosa; Daphne Szeto; Gail Forrest; Barry Campbell; Richard Kennan; Shubing Wang; Chin-Hu Huang; Loise Gichuru; Xiaoli Ping; Xiaolan Shen; Kersten Small; Jeffrey Madwed; Joseph J Lynch
Journal:  SAGE Open Med       Date:  2017-03-30

4.  Effects of occlusal disharmony on cardiac fibrosis, myocyte apoptosis and myocyte oxidative DNA damage in mice.

Authors:  Yuka Yagisawa; Kenji Suita; Yoshiki Ohnuki; Misao Ishikawa; Yasumasa Mototani; Aiko Ito; Ichiro Matsuo; Yoshio Hayakawa; Megumi Nariyama; Daisuke Umeki; Yasutake Saeki; Yasuharu Amitani; Yoshiki Nakamura; Hiroshi Tomonari; Satoshi Okumura
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

5.  Effects of occlusal disharmony on susceptibility to atrial fibrillation in mice.

Authors:  Kenji Suita; Yuka Yagisawa; Yoshiki Ohnuki; Daisuke Umeki; Megumi Nariyama; Aiko Ito; Yoshio Hayakawa; Ichiro Matsuo; Yasumasa Mototani; Yasutake Saeki; Satoshi Okumura
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.